Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13992916 | 0.91 | CHRM3 (0.48) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL4360565 | 0.90 | CHRM2 (0.52) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL27147241 | 0.89 | PLA2G10 (0.41) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL3799622 | 0.89 | PLA2G10 (0.41) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL3470166 | 0.89 | PLA2G10 (0.41) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL13992909 | 0.88 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL26090256 | 0.87 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL6219928 | 0.87 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL1088524 | 0.87 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL578032 | 0.86 | CHRM2 (0.55) | CHRM2CHRM4CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217537-A1 | TERTIARY AMINE COMPOUND AS WELL AS PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-112313207-B | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-109311880-B | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-112313207-A | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-2712863-B1 | Novel inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | CHRM2 4807/4885CHRM4 4838/4885CHRM1 4827/4885 |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | TYMP, RECQL, DPYD | CHRM2 3673/4885CHRM4 4086/4885CHRM1 2866/4885 |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | BLVRB, MMP8, PGLS | CHRM2 4788/4885CHRM4 4733/4885CHRM1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.